RWD20 Analysis of US Real World Evidence Data to Assess and Compare the Effectiveness of Two Chemotherapy Regimens: FOLFIRINOX Vs Gemcitabine/Nab-paclitaxel for First Line Metastatic Pancreatic Cancer

To demonstrate the validity of our analysis techniques utilizing real-world data to assess and compare the effectiveness of two chemotherapy regimens that have not been directly compared in randomized clinical trials: FOLFIRINOX (combined leucovorin calcium, fluorouracil, irinotecan and oxaliplatin) and gemcitabine plus nab-paclitaxel for first line metastatic pancreatic cancer.